This study aimed to determine whether the pluripotency marker SSEA3 and the mesenchymal marker CD105 positivity are associated with the therapeutic efficacy of human neural crest-derived nasal turbinate stem cells (NTSCs) for AD.<h4>Methods</h4>The therapeutic effects of NTSCs obtained from different donors, with varying percentages of SSEA3<sup>+</sup>/CD105<sup>+</sup> cells, were explored in 5 × FAD transgenic AD mice and cerebral organoids derived from induced pluripotent stem cells (iPSC) of three AD patients. This evidence concerns the gene ENG and Alzheimer disease.